M&A Deal Summary |
|
|---|---|
| Date | 2006-11-22 |
| Target | OREXIGEN Therapeutics |
| Sector | Life Science |
| Buyer(s) |
Montreux Equity Partners
MPE Partners |
| Deal Type | Buyout (LBO, MBO, MBI) |
| Deal Value | 30M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Montreux Equity Partners is a growth investment firm focused on investing in commercial stage companies with category leading products, technologies, and services. Montreux Equity Partners looks to invest $10 to $20 million in fast growing companies with $5 to $50 million in revenue. Montreux Equity Partners was formed in 1993 and is headquartered in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 27 |
| Sector (Life Science) | 4 of 8 |
| Type (Buyout (LBO, MBO, MBI)) | 1 of 3 |
| State (California) | 11 of 20 |
| Country (United States) | 11 of 25 |
| Year (2006) | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-01-01 |
Avantis Medical Systems
San Jose, California, United States Avantis Medical Systems, Inc. develops and manufactures catheter-based endoscopic devices. Its initial focus is on devices for use in both detecting and treating cancers of the gastrointestinal (GI) tract. Avantis Medical Systems was founded in 2004 and is based in San Jose, California. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
Cerexa
Oakland, California, United States Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections. |
Sell | $480M |
| Category | Private Equity Firm |
|---|---|
| Founded | 1968 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Agnostic |
Morgenthaler is a Midwest based investment firm focused on venture capital and private equity investments. Morgenthaler's private equity group invests in profitable, lower middle-market businesses in the form of management led buyouts, leveraged build-ups, or recapitalization. The Group looks for stand-alone companies operating in the 'high-value' manufacturing or business services sectors. Morgenthaler seeks transactions valued from $25 to $250 million and EBITDA of excess $5 million. The Group will consider opportunities throughout North America, Europe, and Asia. Morgenthaler has offices in Cleveland, Ohio and Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 82 |
| Sector (Life Science) | 4 of 13 |
| Type (Buyout (LBO, MBO, MBI)) | 4 of 9 |
| State (California) | 16 of 26 |
| Country (United States) | 36 of 78 |
| Year (2006) | 6 of 6 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-11-10 |
Solta Medical
Hayward, California, United States Solta Medical, Inc. is a designer, developer, manufacturer and marketer of medical devices for the non-invasive treatment of wrinkles. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-13 |
Trellis Bioscience
South San Francisco, California, United States Trellis Bioscience is a biotechnology company that developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics. |
Buy | - |
